Stress-echocardiography for observation of the cardiac function in patients receiving Anthrazykline-chemotherapy for malignant thoracic tumors;Durchführbarkeit der stressechokardiographie zur früherkennung der anthracyclin-induzierten kardiomyopathie

Pneumologie

Volumn 55, Issue 8, 2001, Pages 385-389

  Herth, F ^a   Schulz, M R ^b   Manegold, C ^a   Becker, H D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b I Medizinische Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DOBUTAMINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EARLY DIAGNOSIS; FEMALE; HEART VENTRICLE WALL MOTION; HUMAN; LUNG CARCINOMA; LYMPHOMA; MALE; MUCOSA INFLAMMATION; PATIENT MONITORING; PRIORITY JOURNAL; STRESS ECHOCARDIOGRAPHY;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CARDIOMYOPATHIES; DOBUTAMINE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; MIDDLE AGED; SYSTOLE; THORACIC NEOPLASMS;

EID: 0034880457     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-16203     Document Type: Article

References (33)

1. Dobutamine stress echocardiography
2. Echocardiography in adriamycin cardiotoxicity
3. Dose-effect and structure function relationships in doxorubicin cardiomyopathy
4. Clinical spectrum of Anthrazykline antibiotic for cardiotoxicity
5. Morphological changes and catalase activity in the hearts of CD1 mice following acute starvation or single doses of Doxorubicin, Epirubicin or Mitoxantrone
6. Anthrazykline cardiotoxicity
7. Early Detection of Anthrazykline cardiotoxicity in children with acute leukemia using exercise based echocardiography and doppler echocardiography
8. Anthrazykline-induced cardiotoxicity - A review
9. Comparison of left ventricular function by echocardiographic automated border detection and by radionuclide ejection fraction
10. Digital supine bicycle stress echocardiography. A new technique for evaluating coronary artery disease
11. Radionuklidventrikulographie zur verlaufskontrolle bei kardiotoxischer chemotherapie. Reicht die bestimmung der auswurffraktion in ruhe aus?
12. Dobutamine Stress Echocardiography: A sensitive indicator of diminished function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer
13. Beurteilung der adriamycin-kardiotoxizität mittels der äquilibrium-radionuklid-ventrikulographie
14. Belastungs-echokardiographie - Ein neuer test zur erfassung einer anti-ischämischen medikamentenwirkung
15. Stress echocardiography. New techniques
16. Vergleich von belastungsechokardiographie und radionuklidventrikulographie in der diagnostik der kardiomyopathie bei patienten mit malignen erkrankungen unter chemotherapie
17. Sensitivity and specifity of radionuclide ejections fractions in doxirubicin cardiotoxicity
18. Exercise Echocardiography for evaluation of patients after nonsurgical coronary artery revascularization
19. Normalwerte der globalen und regionalen myokardfunktion für die belastungsechokardiographie
20. Adriamycin (NSC-123127) cardiomyopathy. An overview with determination of risk factors
21. Prospective evaluation of doxorubicin cardioloxicity by rest and exercise radionuclide angiography
22. Adriamycin cardiotoxicity. A survey of 1273 patients
23. Vergleichende echokardiographische untersuchungen am herzen des leistungssportlers und des nichttrainierten
24. Kardiotoxische nebenwirkungen von zytostatika. Die anthrazyklin-kardiotoxizität
25. Limitations of comparing left ventricular volumes by two-dimensional echocardiography, myocardial markers and cineangiography
26. Congestive heart failure and left ventricular dysfunction complicating Doxorubicin therapy
27. Guidelines for cardiac monitoring of children during and after Anthrazykline therapy: Report of the cardiology committee of the childrens cancer study group
28. Cardiac toxicity 4 to 20 years after completing Anthrazykline therapy
29. Evaluation of cardiac toxicity of idarubicin
30. Risk factors for doxorubicin-induced congestive heart failure
31. The cardiotoxicity of anticancer agents
32. Exercise echocardiography in the detection of Anthrazykline cardiotoxicity